A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

NCT ID: NCT07329972

Last Updated: 2026-01-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-11-21
• Study Completion Date: 2026-02-04

Brief Summary

This study is a phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation in healthy male and female participants.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Sequence 1

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 1

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Sequence 2

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 1

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Sequence 3

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 1

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Sequence 4

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 1

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Sequence 5

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 2

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Sequence 6

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 2

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Sequence 7

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 2

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Sequence 8

Group Type: EXPERIMENTAL

ZN-A-1041 Formulation 2

Intervention Type: DRUG

Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.

Rabeprazole

Intervention Type: DRUG

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Interventions

ZN-A-1041 Formulation 1

Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.

Intervention Type: DRUG

ZN-A-1041 Formulation 2

Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.

Intervention Type: DRUG

Rabeprazole

Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Body mass index (BMI) within the range of 18 to 32 kg/m2, inclusive
• In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs, as determined by the investigator, at Screening and Check-in, as applicable
• Clinical laboratory evaluations (including chemistry panel, CBC, and UA with complete microscopic analysis) within the normal reference ranges for the certified test laboratory at Screening and Check-in
• Negative test for selected drugs of abuse at Screening and Check-in (includes alcohol)
• Negative hepatitis panel (hepatitis B surface antigen, hepatitis B core antibody, hepatitis B surface antibody [unless consistent with vaccination or immunity due to natural infection], and hepatitis C virus antibody) and negative HIV antibody screens
• For women of childbearing potential: agreement to remain abstinent or use contraception
• For men: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating sperm
• Negative screening test for latent Mycobacterium tuberculosis infection
• Able to swallow and retain multiple tablets without chewing or crushing
• Able to consume the high-fat meal within the protocol-specified time period and willing to consume 100% of the high-fat meal
• Able to fast for 8 hours prior to dosing

Exclusion Criteria

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder, as determined by the investigator
• History or concurrent clinically significant hemorrhagic, bleeding abnormalities, as determined by the investigator
• Personal or family history of congenital long QT syndrome
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
• History of GI surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that uncomplicated appendectomy and hernia repair will be allowed
• History of myocardial infarction
• History of febrile illness within 10 days prior to the first dose of study drug, or participants with evidence of active systemic infection, as determined by the investigator
• History of acute GI symptoms (e.g., nausea, vomiting, diarrhea, heartburn) as determined by the investigator (or designee) at Screening or Check-in
• History of ophthalmological disease or clinically significant abnormality in the ophthalmic examination as determined by the investigator, optometrist, or ophthalmologist
• Risk for suicidal behavior at Screening as determined by the investigator's clinical assessment and an answer "Yes" to item 4 or 5 within 2 years of Screening, or to suicidal behavior items on the Baseline/Screening version C-SSRS or suicide attempt within 2 years of screening. Non-suicidal self-injurious behavior is not exclusionary.
• Have significantly impaired hepatic function (at Screening or Check-in)
• Female who is pregnant or breastfeeding or intending to become pregnant during the study or within 90 days following the final ZN-A-1041 administration
• Have a corrected QT (QTc) interval corrected through use of Fredericia's formula >450 msec for males or >470 for females, PR interval >210 msec, QRS complex >120 msec, or heart rate <50 bpm (at Screening or Check-in)
• History or presence of an abnormal ECG that, in the investigator's opinion, is clinically significant, such as symptomatic bradyarrhythmias, bradycardia, or heart block as determined from 12-lead ECG (at Screening, Check-in, or Day 1 predose). Abnormal results can be confirmed by one repeat 12-lead ECG
• History of alcoholism or drug addiction within 1 year prior to Check-in, use of drugs of abuse (including opioids) within 4 weeks of Screening, and/or positive alcohol breath test and/or urinary drug screen at Screening or Check-in
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives or 90 days, whichever is longer, prior to Check-in
• Treatment with intravenous (IV) antibiotics within 8 weeks prior to Screening and/or treatment with oral antibiotics within 4 weeks prior to Screening
• Use of any drugs known to be moderate or strong inhibitors or inducers of CYP3A or CYP2C8 within 30 days prior to Check-in
• Use of any other prescription medications/products or vaccines (including seasonal flu, H1N1, and coronavirus 2019 [COVID-19] vaccines) other than oral, implantable, transdermal, and injectable contraceptives or medications administered during the ophthalmic examination within 14 days prior to Check-in, unless deemed acceptable by the investigator
• Use of therapeutic anticoagulation or thrombolytic anticoagulants within 14 days prior to Check-in
• Use of any over-the-counter, non-prescription medications (including vitamins; minerals; and phytotherapeutic-, herbal-, and plant-derived preparations) within 7 days prior to Check-in, unless deemed acceptable by the investigator
• Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 3 months prior to Check-in or a positive cotinine test
• Use of poppy seed-, grapefruit-, star fruit-, pomegranate-, pawpaw-, or Seville orange-containing foods or beverages within 7 days prior to Check-in
• Use of alcohol- or caffeine-containing foods or beverages within 48 hours prior to Check-in, unless deemed acceptable by the investigator
• Participant is not willing to minimize or avoid exposure to natural or artificial sunlight (tanning beds or ultraviolet (UV) A/B treatment) following administration of study drug through 5 days following the final ZN-A-1041 administration
• Participant is not willing to refrain from strenuous exercise from 7 days prior to Check-in and during the period of confinement at the study site (e.g., will not begin a new exercise program or participate in any unusually strenuous physical exertion)
• Poor peripheral venous access as determined by the investigator
• History of malignancy within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix or basal cell skin cancer)
• Donation of blood within 3 months prior to Screening through study completion, donation of plasma within 2 weeks prior to Screening through study completion, or donation of platelets within 6 weeks prior to Screening through study completion
• Receipt of blood products within 2 months prior to Screening and during the entire study duration
• Participants who, in the opinion of the investigator (or designee), should not participate in this clinical study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Daytona Beach Clinical Rsch Unit

Daytona Beach, Florida, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Reference Study ID Number: GP46367 https://forpatients.roche.com/

Role: CONTACT

global-roche-genentech-trials@gene.com

888-662-6728 (U.S. only)

Other Identifiers

GP46367

Identifier Type: -

Identifier Source: org_study_id